Sub-Classification of Triple-Negative Breast Cancer using Androgen Receptor and Cytokeratin 5/6
Leonard Derkyi-Kwarteng, L. Ahenkorah Fondjo, P. Kafui Akakpo, Eric Aidoo, Ato Brown, Ellen Ola, Stephanie K. A. Adjei, Francis Agyemang
Journal of Cancer and Tumor International · pp. 44–51 · Published 22 Jul 2022
10.9734/jcti/2022/v12i330181Abstract
Background: Triple negative breast cancer (TNBC) is a unique heterogenous subtypes of breast cancer which is characterized by negative estrogen, progesterone, and human epidermal growth factor receptor (HER-2) status. TNBC displays different molecular phenotype with which basal-like tumour can be identified using high molecular weight basal cytokeratin 5/6 (CK5/6). Methods: Ninety-five (95) formalin fixed cases from Korle Bu Teaching Hospital in Ghana’s (KBTH) archives were sampled in a retrospective study from 2012-2016. Blocks of these triple-negative breast cancer was subclassified using CK5/6 and Androgen Receptor (AR) antibodies. Subclasses were also identified. Results and Conclusion: In all ninety-five (95) TNBC cases, hormonal subtyping was sub-classified using CK 5/6 and AR. The mean ±SD of these cases was recorded as 53.96 (±13.56) years and the age range of these cases was 22-104 years. The average size (±SD) of the tumour was recorded to be 14.43(±7.62) and it had a range of 2.4-45cm. lymph nodes retrieved also had a mean ± SD of 10.35(±6.05) with an average tumour lymph nodes involvement of 2.6(± 3.697). Invasive Ductal carcinoma was identified as the commonest histologic type of TNBC with approximately 95% of the cases. This was followed by invasive lobular (2.1%), medullary carcinoma (2.1%) and metaplastic carcinoma (1.1%). Approximately 30% of TNBC stained positive for CK5/6. It can however be concluded that, most TNBC are not basal-like when the basal marker CK5/6 is used.
References (23)
- 1 Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence [DOI]
- 2 Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma [DOI]
- 3 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [DOI]
- 4 Breast cancer prognostic classification in the molecular era: the role of histological grade [DOI]
- 5 Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer [DOI]
- 6 TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer [DOI]
- 7 Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes [DOI]
- 8 Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis [DOI]
- 9 What is triple-negative breast cancer? [DOI]
- 10 Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation [DOI]
- 11 African ancestry and higher prevalence of triple‐negative breast cancer [DOI]
- 12 Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study [DOI]
- 13 Novel therapeutic strategies in the treatment of triple-negative breast cancer [DOI]
- 14 Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers [DOI]
- 15 Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation [DOI]
- 16 The Predictive Role of E-cadherin and Androgen Receptor on In Vitro Chemosensitivity in Triple-negative Breast Cancer [DOI]
- 17 Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers [DOI]
- 18 Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population [DOI]
- 19 Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin [DOI]
- 20 Clinical significance of morphologic characteristics in triple negative breast cancer [DOI]
- 21 Phyllodes Tumor of the Breast: Analysis of 48 Patients [DOI]
- 22 Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer [DOI]
- 23 EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter [DOI]
Cited by 0
No indexed citations yet.
Related research
- Hyperlipidic Diet-induced Obesity Increased Proliferative Signals- AR, ERK1/2- on Mice Prostate, Which can be Restored through Physical Training — shares topic coverage
- Expressional Evaluation of Androgen Receptor in Transitional Cell Carcinoma of Urinary Bladder Patients — shares topic coverage
- A Review on the Protective Effects of Vitamin D\(_3\) and It's Analog against Hepatocellular Carcinoma, in vivo and in vitro — shares topic coverage
- In silico Analysis of Andrographolide, a Bioactive Compound of Andrographis paniculata, against the Androgen Receptor and Steroid 17-alpha-hydroxylase/17,20 Lyase as an Anti-prostate Cancer Agent — shares topic coverage
- Gene Expression Profiling of Triple Negative Breast Cancer Cells Treated with Afatinib — shares topic coverage
Article metrics
Real usage data collected on this platform.
12
Page views
0
PDF downloads
1
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.